Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).

Aspirin, rivaroxaban similarly effective for preventing venous thromboembolism

21 Mar 2018

Aspirin is as effective as rivaroxaban in the prevention of symptomatic venous thromboembolism following total hip or total knee arthroplasty in patients who have already received 5 days of rivaroxaban prophylaxis, according to a study.

A total of 3,424 patients who underwent total hip or knee arthroplasty received once-daily oral rivaroxaban (10 mg) until postoperative day 5, and were then randomly assigned to either continue rivaroxaban or switch to aspirin (81 mg) for 9 days in the total knee arthroplasty group (n=1,620) or for 30 days in the total hip arthroplasty group (n=1,804).

All patients were followed for 90 days for symptomatic venous thromboembolism (main efficacy outcome) and bleeding complications, including major or clinically relevant nonmajor bleeding (main safety outcome).

Venous thromboembolism occurred in 11 of 1,707 patients (0.64 percent) who received aspirin vs 12 of 1,717 patients (0.70 percent) who received rivaroxaban (difference, 0.06 percentage points; 95 percent CI, −0.55 to 0.66; p<0.001 for noninferiority and p=0.84 for superiority).

Major bleeding complications were documented in eight patients (0.47 percent) on aspirin vs five patients (0.29 percent) on rivaroxaban (difference, 0.18 percentage points; −0.65 to 0.29; p=0.42).

Clinically important bleeding occurred in 22 patients (1.29 percent) on aspirin vs 17 patients (0.99 percent) on rivaroxaban (difference, 0.30 percentage points; −1.07 to 0.47; p=0.43).

Deep-vein thrombosis and pulmonary embolism (collectively called venous thromboembolism) are known complications after total hip or total knee arthroplasty. The perioperative administration of anticoagulant prophylaxis has been shown to effectively reduce the rates of death and complications associated with venous thromboembolism after such procedures. Aspirin, an inexpensive and widely available antiplatelet drug, has also been shown to be effective in the postoperative prevention of venous thromboembolism. [Chest 2008;133:381S-453S; Arch Intern Med 2003;163:1362-1366]

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 31 Dec 2019
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
23 Dec 2019
At a Menarini-sponsored symposium held during the Asian Pacific Society Congress, renowned cardiologist Prof John Camm provided the latest evidence for chronic stable angina with or without concomitant diseases, with a special focus on the antianginal agent ranolazine and combination therapies. The event was chaired and moderated by Dr Dante Morales from the University of the Philippines College of Medicine.
Pearl Toh, 13 Jan 2020
Obeticholic acid significantly improves fibrosis and disease activity in patients with nonalcoholic steatohepatitis (NASH), a chronic liver disease currently with no approved therapy, according to an interim analysis of the landmark REGENERATE* study.
Stephen Padilla, 6 days ago
The Lancet Commission on Hypertension Group has recently released a position statement that contains a list of recommendations for the improvement of accuracy standards for devices that measure blood pressure (BP).